Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 185 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Givinostat for Duchenne muscular dystrophy	Givinostat	Duchenne muscular dystrophy (DMD)	Genetic Disorders , Musculoskeletal System	2023	View \| Download
Golimumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years	Golimumab	Ulcerative colitis	Gastroenterology	2023	View \| Download
Human C1-esterase inhibitor (subcutaneous injection) for preventing hereditary angioedema	Human C1 esterase inhibitor (Berinert)	Hereditary angioedema (HAE)	Genetic Disorders , Immunology	2023	View \| Download
Hydromethylthionine mesylate for Alzheimer's disease	Hydromethylthionine mesylate (LMTX;TRx-0237)	Alzheimer's disease	Neurology	2023	View \| Download
I-131-Apamistamab for acute myeloid leukaemia	I-131-Apamistamab (Iomab-B)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2023	View \| Download
IcoSema for treating adults with type 2 diabetes	IcoSema (NN1535)	Type 2 diabetes	Endocrine Nutritional and Metabolic Disorders	2023	View \| Download
Imlunestrant with or without abemaciclib for treating ER-positive, HER2-negative locally advanced or metastatic breast cancer after endocrine therapy	Imlunestrant	Breast cancer	Breast Cancer	2023	View \| Download
Invimestrocel for Acute ischaemic stroke	Multistem(PF05285401;HLCM05;invimestrocel)	Acute ischaemic stroke	Cardiovascular System	2023	View \| Download
Iptacopan for treating complement 3 glomerulopathy	Iptacopan	Complement 3 glomerulopathy	Immunology , Neurology	2023	View \| Download
Isatuximab induction therapy with bortezomib, lenalidomide and dexamethasone for previously untreated multiple myeloma	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2023	View \| Download